NSE: CIPLA | BSE: 500087

Mid-range Performer

Download real time

1397.50 -37.00 (-2.58%)

High volume today

NSE 16 Jan, 2026 3:31 PM (IST)

112,886.1

Market Cap

High in industry

Beta 1Year

Low volatility

Analyst Downgrade

Nuvama downgrades Cipla to a 'Reduce' rating; cuts the target price to Rs 1,360 See details

Cipla Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for CIPLA, BSE:500087 Cipla Ltd.

Search Inside the pdf :

Cipla Ltd.

23 Dec 2025

1397.50

-2.58%

CIPLA LTD

Hold: Cipla Ltd.

Recommendation Target

Geojit BNP Paribas

Cipla Ltd delivered a steady Q2FY26 performance, supported by strong branded generics in India and continued leadership in its US respiratory business (albuterol MDI). The company's strategic focus on high-growth therapies such as obesity and diabetes (exclusive launch of Tirzepatide Yurpeak in India) underpins its long-term growth potential. However, near-term challenges remain, including the anticipated revenue erosion from the Revlimid cliff, increased R&D intensity weighing on margins, and execution risk related to timely approvals, which could limit earnings visibility and margin recovery in the medium term, thereby warranting a more...

Cipla Ltd. is trading below all available SMAs

Cipla Ltd.

04 Nov 2025

1397.50

-2.58%

Growth outlook intact despite near-term headwinds

Accumulate: Cipla Ltd.

Target

Deven Choksey

Cipla’s near-to-medium term outlook remains positive, underpinned by strong execution in domestic formulations and a visible ramp-up in complex generics and biosimilars in the U.S. market.

Number of FII/FPI investors decreased from 1124 to 1085 in Sep 2025 qtr

Cipla Ltd.

31 Oct 2025

1397.50

-2.58%

Cipla (CIPLA IN) Q2FY26 Result Update Higher R&D...

Accumulate: Cipla Ltd.

Recommendation Target

Prabhudas Lilladhar

Cipla Ltd. is trading below all available SMAs

Cipla Ltd.

31 Oct 2025

1397.50

-2.58%

Result Update:Cipla

Buy: Cipla Ltd.

Axis Direct

We remain positive on the stock with a BUY rating and arrive at a TP of Rs 1,700/share.

Cipla Ltd. has an average target of 1697.44 from 9 brokers.

Cipla Ltd.

31 Oct 2025

1397.50

-2.58%

Cipla Ltd.

Buy: Cipla Ltd.

Target

ICICI Direct

The revenues were largely in line except India which was impacted by lower acute respiratory sales. The management is confident of better performance from India in the ensuing quarters. FY26 is likely to be a year of some consolidation with the genericization of gRevlimid and flattish US sales as major launches are expected to pick up momentum in FY27. On the EBITDA margins front, the management is guiding a range of 22.7524% which is slightly below the H1 exit range, due to lower Lenalidomide sales and higher R&D. The future remains bright as the company expects critical launches such as gAdvair (respiratory) by H2FY26 and also has a...

Cipla Ltd. is trading at high day volume of 4.3M.

Cipla Ltd.

08 Sep 2025

1397.50

-2.58%

Growth outlook intact despite near-term headwinds

Hold: Cipla Ltd.

Deven Choksey

We have revised our FY26E/FY27E EPS estimates by +0.9%/-5.2%, as we factor in lower revenue on account of ramp down of Revlimid portfolio and ongoing price erosion in the US market, higher depreciation and amortization expense, offset by higher other income.

Number of FII/FPI investors decreased from 1124 to 1085 in Sep 2025 qtr

Cipla Ltd.

02 Sep 2025

1397.50

-2.58%

India, RoW biz to stay steady, US drug pipeline - the next trigger

Buy: Cipla Ltd.

Target

Sharekhan

Cipla has robust domestic and global product pipelines. US product pipeline to be healthy and will be key to driving growth from H2FY26E and contribute significantly from FY27E onwards.

Number of FII/FPI investors decreased from 1124 to 1085 in Sep 2025 qtr

Cipla Ltd.

28 Jul 2025

1397.50

-2.58%

Result Update:Cipla

Buy: Cipla Ltd.

Axis Direct

We remain positive on the stock with a BUY rating and arrive at a target price of Rs 1,700 per share.

Cipla Ltd. is trading below all available SMAs

Cipla Ltd.

27 Jul 2025

1397.50

-2.58%

Cipla (CIPLA IN) Q1FY26 Result Update Strong US...

Buy: Cipla Ltd.

Prabhudas Lilladhar

CIPLA's Q1FY26 EBITDA (Rs17.8bn; 25.6% OPM) was 6% ahead of our estimates. Cipla managed to deliver strong margins during the quarter. During the quarter company witnessed price erosion for its generic products which was offset by new launches such as gAbraxane. Mgmt guided strong US revenues of $1bn for FY27 despite gRevlimid erosion. We expect Cipla to maintain its existing US sales run-rate. This will be aided by several high value niche launches in the US like gAbraxane, Nilotininb, gAdvair. Further, Cipla's...

Cipla Ltd. is trading at high day volume of 4.3M.

Cipla Ltd.

26 Jul 2025

1397.50

-2.58%

US business on a strong footing

Buy: Cipla Ltd.

Target

ICICI Securities Limited

Cipla reported an in-line Q1FY26 result led by growth across the US and South Africa. Despite price erosion in gRevlimid, it posted a 156bps YoY (+133bps QoQ) surge in gross margin to 68.8%.

Cipla Ltd. is trading at high day volume of 4.3M.

Is Cipla Ltd. worth buying?

640 Votes:

Buy 75.94%

Sell 13.59%

Hold 10.47%

RESEARCH REPORTS

Hold SEE REPORTS >

pdf

Accumulate SEE REPORTS >

pdf